Cart
sales@molnova.com
ISOBUTYRALDEHYDE OXIME
CAS No. 151-00-8
ISOBUTYRALDEHYDE OXIME( —— )
Catalog No. M19919 CAS No. 151-00-8
2-methylpropanal oxime is an aldoxime derived from 2-methylpropanal. It derives from an isobutyraldehyde.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 10MG | 71 | In Stock |
|
| 25MG | 122 | In Stock |
|
| 50MG | 179 | In Stock |
|
| 100MG | 267 | In Stock |
|
| 200MG | 401 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameISOBUTYRALDEHYDE OXIME
-
NoteResearch use only, not for human use.
-
Brief Description2-methylpropanal oxime is an aldoxime derived from 2-methylpropanal. It derives from an isobutyraldehyde.
-
Description2-methylpropanal oxime is an aldoxime derived from 2-methylpropanal. It derives from an isobutyraldehyde.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number151-00-8
-
Formula Weight87.12
-
Molecular FormulaC4H9NO
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCC(C)C=NO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Moxonidine
Moxonidine is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.
-
Boc-NH-PEG12-CH2CH2C...
Boc-NH-PEG12-CH2CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Nogo-66 (1-40)
Peptide fragment corresponding to residues 1 - 40 of Nogo-66, the domain of the myelin protein Nogo that inhibits axonal outgrowth. Acts as a competitive antagonist at the Nogo-66 receptor (NgR); blocks Nogo-66- and CNS myelin-induced inhibition of axonal growth, but does not reduce myelin-associated glycoprotein (MAG) inhibition of neurite outgrowth in vitro. Promotes regeneration of hemisected spinal axons and locomotor recovery following spinal injury in vivo.
